Amylyx Pharmaceuticals, Inc.
SEC CIK 1658551 · AMLX · last insider filing 2026-06-08
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Milne George M JR | Director | filed 2022 - 2026 |
| Quimi Daphne | Director | filed 2022 - 2026 |
| Fonteyne Paul R. | Director | filed 2022 - 2026 |
| Firestone Karen | Director | filed 2023 - 2026 |
| Zeiher Bernhardt G | Director | filed 2024 - 2026 |
| Klee Justin B. | Director · Co-Chief Executive Officer | filed 2022 - 2026 |
| Cohen Joshua B | Director · Co-Chief Executive Officer | filed 2022 - 2026 |
| Cheng Isaac | Director | filed 2022 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Frates James M | Chief Financial Officer | filed 2022 - 2026 |
| Bedrosian Camille L | Chief Medical Officer | filed 2023 - 2026 |
| Mazzariello Gina | Chief Legal Officer | filed 2022 - 2026 |
| Yeramian Patrick D | Chief Medical Officer | filed 2022 - 2024 |
| Olinger Margaret | Chief Commercial Officer | filed 2022 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.